- VIM0423, a potential first-in-class oral medicine for isolated dystonia, is currently being studied in a Phase 1 clinical trial; Phase 2 planned for fourth quarter of 2025 CAMBRIDGE, Mass., May 29, ...

NICE, France — Depression is the strongest long-term predictor of health-related quality of life (HR-QoL), followed by generalized anxiety disorder (GAD), for patients with isolated dystonia, a new ...

Researchers at Mass Eye and Ear have developed a unique diagnostic tool that can detect dystonia from MRI scans, the first technology of its kind to provide an objective diagnosis of the disorder.

Researchers at Mass Eye and Ear have developed a unique diagnostic tool that can detect dystonia from MRI scans, the first technology of its kind to provide an objective diagnosis of the disorder.

(MENAFN- The Conversation) When we think of movement disorders, the tremors associated with Parkinson's disease are probably what first spring to mind. However, there are other equally debilitating ...

Dystonia can affect everyone, from small children to older adults. Childhood dystonia is usually generalized dystonia (affecting most body parts). It is usually caused by genetic factors, while ...

Sodium oxybate provided temporary relief for laryngeal dystonia patients who were alcohol-responsive. The neurologic disorder causes laryngeal muscle spasms, leading to a chronically strained voice.

For the first time, researchers have shown that, in patients with a type of movement disorder known as dystonia, a particular pattern of brain activity is linked to both the severity of symptoms and ...

In an interview with HT Lifestyle, Dr Pankaj Agarwal, Head of the Department of Neurology at Gleneagles Hospital in Mumbai's Parel, shared, “Patients suffering from them can be quite debilitated by ...

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, launched today with a $60M Series A ...

(MENAFN- GlobeNewsWire - Nasdaq) - $60 million Series A led by Atlas Venture, and founded by an expert team of physicians and scientists - VIM0423, a potential first-in-class oral medicine for ...